米托蒽醌联合长春新碱治疗白血病的有效性及对患者QOL评分的影响(1)
[摘要] 目的 探讨米托蒽醌联合长春新碱治疗白血病的有效性及对患者的生活质量量表(Quality of Life，QOL)评分的影响。 方法 选择2016年2月～2018年3月于我院接受治疗的白血病患者70例，依照随机数字表法分为观察组(35例)与对照组(35例)。对照组采用柔红霉素联合长春新碱治疗，观察组采用米托蒽醌联合长春新碱治疗，对比两组治疗后总有效率与治疗前后QOL评分。 结果 与对照组相比，观察组治疗后总有效率较高，差异有统计学意义(P<0.05);治疗后，两组患者QOL评分较治疗前高，且观察组QOL评分较对照组高，差异有统计学意义(P<0.05)。 结论 米托蒽醌联合长春新碱治疗白血病的临床效果显著，能有效提高患者的生活质量。
[关键词] 白血病;米托蒽醌;长春新碱;生活质量
[中图分类号] R733.71 [文献标识码] B [文章编号] 1673-9701(2019)28-0044-03
[Abstract] Objective To investigate the effectiveness of mitoxantrone combined with vincristine in the treatment of leukemia and its impact on the quality of life (QOL) score. Methods 70 patients with leukemia who were treated in our hospital from February 2016 to March 2018 were selected. The patients were assigned to the observation group(35 cases) and the control group(35 cases) according to the random number table method.The control group was given daunorubicin combined with vincristine for treatment.The observation group was given mitoxantrone combined with vincristine for treatment. The total effective rate after treatment and the QOL scores before and after treatment were compared between the two groups. Results Compared with the control group， the total effective rate in the observation group was higher after treatment， and the difference was statistically significant(P<0.05); after treatment， the QOL scores in both groups were higher than those before treatment. The QOL score in the observation group was higher than that in the control group， and the difference was statistically significant(P<0.05). Conclusion The clinical effect of mitoxantrone combined with vincristine in the treatment of leukemia is significant and can effectively improve the quality of life of patients.
[Key words] Leukemia; Mitoxantrone; Vincristine; Quality of life
白血病為造血干细胞恶性克隆性疾病，患者会出现贫血、出血以及一系列的感染等临床表现。白血病致死率较高，且相关医学研究显示，每年全球被确诊为白血病患者大约为25万，是全部癌症患者的1/4，而我国国内的白血病患者也在逐年增长，每年约增加4万例[1]。米托蒽醌类属蒽环类抗肿瘤药物，为合成药，抗肿瘤活性较高，是治疗白血病的常见药物。长春新碱则是由长春花中提取出的生物碱所制成的一种抗肿瘤制剂。本项研究旨在探讨米托蒽醌联合长春新碱治疗白血病的有效性及对患者的生活质量量表(Quality of life，QOL)评分的影响。现报道如下。
1 资料与方法
1.1 一般资料
选择2016年2月～2018年3月于我院接受治疗的白血病患者70例，依照随机数字表法分为观察组(35例)与对照组(35例)。观察组男21例，女14例;年龄18～64岁，平均(38.32±5.36)岁;初次发病29例，复发6例。对照组男22例，女13例;年龄18～65岁，平均(38.62±5.43)岁;初次发病28例，复发7例。两组患者的一般资料相比较，差异无统计学意义(P>0.05)，具有可比性。本项研究已获得我院医学伦理委员会的批准。
1.2 纳入和排除标准
(1)纳入标准[2]：根据《血液病诊断及疗效标准》[3]中的相关诊断标准确诊为淋巴细胞白血病;年龄≥18周岁;本项治疗开始前2周内未使用过任何相关药物;知晓本项研究详情并自愿签署知情同意书。(2)排除标准[4]：存在严重的肝、心或肾功能不全;继发性白血病;对本次研究所用药物存在过敏史;处于妊娠期或哺乳期。, 百拇医药(金英)
[关键词] 白血病;米托蒽醌;长春新碱;生活质量
[中图分类号] R733.71 [文献标识码] B [文章编号] 1673-9701(2019)28-0044-03
[Abstract] Objective To investigate the effectiveness of mitoxantrone combined with vincristine in the treatment of leukemia and its impact on the quality of life (QOL) score. Methods 70 patients with leukemia who were treated in our hospital from February 2016 to March 2018 were selected. The patients were assigned to the observation group(35 cases) and the control group(35 cases) according to the random number table method.The control group was given daunorubicin combined with vincristine for treatment.The observation group was given mitoxantrone combined with vincristine for treatment. The total effective rate after treatment and the QOL scores before and after treatment were compared between the two groups. Results Compared with the control group， the total effective rate in the observation group was higher after treatment， and the difference was statistically significant(P<0.05); after treatment， the QOL scores in both groups were higher than those before treatment. The QOL score in the observation group was higher than that in the control group， and the difference was statistically significant(P<0.05). Conclusion The clinical effect of mitoxantrone combined with vincristine in the treatment of leukemia is significant and can effectively improve the quality of life of patients.
[Key words] Leukemia; Mitoxantrone; Vincristine; Quality of life
白血病為造血干细胞恶性克隆性疾病，患者会出现贫血、出血以及一系列的感染等临床表现。白血病致死率较高，且相关医学研究显示，每年全球被确诊为白血病患者大约为25万，是全部癌症患者的1/4，而我国国内的白血病患者也在逐年增长，每年约增加4万例[1]。米托蒽醌类属蒽环类抗肿瘤药物，为合成药，抗肿瘤活性较高，是治疗白血病的常见药物。长春新碱则是由长春花中提取出的生物碱所制成的一种抗肿瘤制剂。本项研究旨在探讨米托蒽醌联合长春新碱治疗白血病的有效性及对患者的生活质量量表(Quality of life，QOL)评分的影响。现报道如下。
1 资料与方法
1.1 一般资料
选择2016年2月～2018年3月于我院接受治疗的白血病患者70例，依照随机数字表法分为观察组(35例)与对照组(35例)。观察组男21例，女14例;年龄18～64岁，平均(38.32±5.36)岁;初次发病29例，复发6例。对照组男22例，女13例;年龄18～65岁，平均(38.62±5.43)岁;初次发病28例，复发7例。两组患者的一般资料相比较，差异无统计学意义(P>0.05)，具有可比性。本项研究已获得我院医学伦理委员会的批准。
1.2 纳入和排除标准
(1)纳入标准[2]：根据《血液病诊断及疗效标准》[3]中的相关诊断标准确诊为淋巴细胞白血病;年龄≥18周岁;本项治疗开始前2周内未使用过任何相关药物;知晓本项研究详情并自愿签署知情同意书。(2)排除标准[4]：存在严重的肝、心或肾功能不全;继发性白血病;对本次研究所用药物存在过敏史;处于妊娠期或哺乳期。, 百拇医药(金英)